



ASX Announcement | 11 December 2020
Noxopharm Limited (ASX:NOX)

December Investor Webinar Recording

Sydney 11 December 2020: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide the December Investor Webinar as indicated in the ASX announcement dated 8 December 2020.

The webinar can be found by visiting: [Investors | Noxopharm](#)

The key purpose of the webinar was to update the market on the use of funds from the recently completed \$23M capital raise.

The funds are intended to underwrite the Company's R&D activities through into 2022, with those activities falling into 3 broad categories:

1. Three anti-cancer clinical studies - IONIC-1, DARRT-2 and LuPIN clinical studies – seeking to provide proof-of-concept evidence of the immunotherapy effect of Veyonda® to:
 - boost the anti-cancer effects of the checkpoint inhibitor Opdivo® (Bristol-Myers Squibb)
 - boost the anti-cancer effects of the experimental radiopharmaceutical ¹⁷⁷lutetium-PSMA-617 (Novartis)
 - lift the abscopal response rate to radiotherapy from extremely rare to commonplace.
2. A clinical study testing the anti-inflammatory ability of Veyonda to block cytokine release syndrome and septic shock in COVID-19 patients
3. A drug discovery program intended to expand the Company's drug pipeline

The following interviews on the Company's website also explain the Company's plans for 2021:

- The Market Herald Deal Room Interview with Noxopharm CEO and Managing Director Dr Graham Kelly 7 Dec 2020
- Switzer Small and Microcap Conference 2 December 2020

Graham Kelly, CEO and Executive Chairman of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking sepsis.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).



To learn more, please visit: noxopharm.com

Investor & Corporate enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries

Julia Maguire
The Capital Network
E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.